Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EuBalance is a dietary supplement developed by Libytec Pharmaceutical, specifically formulated to support women with Polycystic Ovary Syndrome (PCOS) and metabolic imbalances such as insulin resistance. The product contains a combination of myo-inositol and d-chiro-inositol in a physiological 40:1 ratio, along with folic acid and manganese. The mechanism of action centers on the role of inositol isomers as second messengers in insulin signaling; myo-inositol and d-chiro-inositol help restore insulin sensitivity and regulate glucose metabolism, which are frequently impaired in PCOS patients. Additionally, these components support ovarian function and hormonal balance, potentially improving reproductive outcomes and managing symptoms like irregular cycles and hyperandrogenism. Folic acid is included to support DNA synthesis and homocysteine metabolism, while manganese acts as a cofactor for various metabolic enzymes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EuBalance.